The European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association (ACC/AHA) guidelines support early use of a glycoprotein IIb/IIIa receptor inhibitor such as AGGRASTAT® in combination with heparin and acetylsalicylic acid (ASA) in high-risk patients with acute coronary syndromes (ACS).1,2
ESC and ACC/AHA Acute Coronary Syndromes Guidelines
ECG = electrocardiogram; LMWH = low molecular weight heparin; UFH = unfractionated heparin; GP = glycoprotein; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft
* Omit clopidogrel if the patient is likely to undergo CABG within 5 days
** Depending upon clinical and angiographic features
Adapted from Bertrand et al;1 Braunwald et al.2
MI = myocardial infarction; CRP = C-reactive protein; IL = interleukin
Adapted from Bertrand et al.1
See High-Risk Patients section for additional information on these patient populations.
Early identification and treatment of high-risk patients with AGGRASTAT reduced the risk of death or MI3,4
Early initiation of AGGRASTAT reduced the overall event rate3,4
AGGRASTAT was well tolerated when given in combination with UFH or LMWH5
Acute Coronary Syndromes
ACS is characterized by prolonged (>20 minutes) or repetitive symptoms of cardiac ischemia occurring at rest or with minimal exertion, associated with either ischemic ST-T wave changes on ECG or elevated cardiac enzymes. The definition includes “unstable angina” and “non–Q‑wave MI” but excludes MI associated with Q waves or nontransient ST‑segment elevation.1,2
